secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2025-04-25T23:59:59+00:00
Accession:  0001551152-25-000026
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie Q1 adj EPS $2.46 (+6.5%), revenue $13.34B (+8.4%); raises FY EPS guidance to $12.09-$12.29
--------------------------------------------------------------------------------

- Q1 GAAP EPS $0.72 (down 6.5%), adjusted EPS $2.46 (up 6.5%); revenue $13.34B (+8.4% reported).
- Immunology growth: Skyrizi $3.43B (+70.5%), Rinvoq $1.72B (+57.2%); Humira $1.12B (-50.6%).
- Aesthetics down 11.7% to $1.10B; Botox Cosmetic -12.3%, Juvederm -22.2%.
- FY2025 adjusted diluted EPS guidance raised to $12.09-$12.29 from $11.99-$12.19.
- CEO Robert A. Michael elected chairman effective July 1, 2025, succeeding Richard A. Gonzalez.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000155115225000026/0001551152-25-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000155115225000026/abbv-20250425.htm
  HTML page:      https://secwatch.observer/filing/0001551152-25-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer